non-hodgkin's%20lymphoma
NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Radiotherapy

Indolent Stage I/Contiguous Stage II NHL
  • Studies suggest doses of 25-40 Gy
  • May be given as local or extended-field RT
Aggressive Stage I/Contiguous Stage II NHL
  • Involved site radiation therapy (ISRT) may be given with or without chemotherapy (usually R-CHOP)
    • Studies have shown an increase in the overall survival & event-free survival rates of patients given CHOP with involved-site radiation therapy (ISRT)
Indolent Noncontiguous Stage II/III/IV NHL
  • Studies suggest doses of 25-40 Gy
  • Total body irradiation (TBI), EF-XRT, & TBI followed by high-dose radioimmunotherapy are still under clinical evaluation & needs further studies to prove efficacy in patients with indolent noncontiguous stage II/III/IV NHL
Aggressive Noncontiguous Stage II/III/IV NHL
  • Local-field XRT is recommended with combination chemotherapy
Recurrent NHL
  • Low dose involved site radiation therapy (ISRT) is recommended to indolent/aggressive relapsed NHL patients for palliative purposes
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.